Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.57

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $21.57.

ZVRA has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the transaction, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the stock. MetLife Investment Management LLC grew its holdings in Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after acquiring an additional 1,717 shares during the period. The Manufacturers Life Insurance Company boosted its position in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. IFG Advisors LLC grew its stake in shares of Zevra Therapeutics by 10.0% during the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after purchasing an additional 2,650 shares during the period. Invesco Ltd. increased its holdings in shares of Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after purchasing an additional 3,007 shares in the last quarter. Finally, Corebridge Financial Inc. lifted its stake in shares of Zevra Therapeutics by 16.9% in the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after purchasing an additional 3,801 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Trading Down 1.9 %

NASDAQ:ZVRA opened at $7.68 on Friday. The firm has a 50 day moving average of $8.13 and a 200 day moving average of $8.09. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The stock has a market capitalization of $409.93 million, a price-to-earnings ratio of -3.90 and a beta of 2.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.